NCT03251378: The Evaluation of Safety, Tolerability, and Pharmacokinetics for Fruquintinib in Solid Tumors

NCT03251378
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1
Drug Category: Tyrosine-Kinase Inhibitor

Key Eligibility Criteria:

Gender: All
Age: 18 Years to 75 Years (Adult, Senior)
Location of Metastases: 
Additional Notes: 
Exclusions: Patients with central nervous system (CNS) metastatic disease or prior cerebral metastasis
https://ClinicalTrials.gov/show/NCT03251378

Comments are closed.

Up ↑